US FDA approves KamadaKamada’s application to manufacture Cytogam

04 May 2023
www.pharmaceutical-technology.com
Drug ApprovalImmunotherapy
US FDA approves Kamada’s application to manufacture Cytogam
Preview
Source: Pharmaceutical Technology
Cytogam is indicated for prophylaxis of cytomegalovirus disease associated with pancreas, lung, heart, liver and kidney transplantation. Credit:. Volkova via Shutterstock.com.
The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel.
The regulatory approval represents the completion of the Cytogam technology transfer process from CSL Behring, its previous manufacturer.
Recommended Reports
US FDA approves Kamada’s application to manufacture Cytogam
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ropidoxuridine in Sarcomas GlobalData
US FDA approves Kamada’s application to manufacture Cytogam
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - AVCN-583601 in Epidermolysis Bullosa GlobalData
View all
Kamada stated that the technology transfer supplement includes the manufacture of an upstream protein solution undertaken by Prothya Biosolutions at its facility in Belgium.
Acquired from Saol Therapeutics, Cytogam is indicated for the prophylaxis of cytomegalovirus disease associated with pancreas, lung, heart, liver and kidney transplantations.
It is claimed to be the only immunoglobulin (IgG) product to receive FDA approval for this indication.
In 2022, the therapy generated $23m in sales.
Kamada CEO Amir London stated: “The US FDA approval of this application to manufacture Cytogam, which was granted within our expected timeline following a successful on-site inspection by the FDA, represents a significant accomplishment for KamadaKamada.
“This is the third product, in addition to Glassia and Kedrab, to be approved by the FDA for manufacturing at our Israeli site.
“We intend to initiate commercial manufacturing of Cytogam at our Israeli facility shortly, which will positively impact the facility’s utilisation and efficiency.”
In January 2023, the company submitted a similar technology transfer application to the Canadian health authorities, where it is now under review.
In 2020, Kamada collaborated with Kedrion Biopharma in the development, manufacture and distribution of a human plasma-derived polyclonal IgG product to treat Covid-19.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.